Session type: Parallel sessions
In the last four years, five new drugs, representing four different classes of agents with unique mechanisms of action have been licensed for the treatment of metastatic melanoma, each representing step changes in improving outcomes from this deadly disease. These remarkable clinical benefits arise from extensive preclinical research unravelling the mechanisms of normal and abnormal melanoma cell proliferation. Key challenges in terms of innate and acquired resistance have yet to be overcome. In this session, the use of melanoma models to better understand the microenvironment and tumour heterogeneity will be discussed.